Recently Featured

UCB reveals Bimzelx’s superiority over Skyrizi in psoriatic arthritis trial

June 16, 2026
UCB has announced significant findings from its phase 3b trial of Bimzelx, demonstrating its efficacy in treating psoriatic arthritis compared to AbbVie’s Skyrizi. In this head-to-head study, 49% of patients receiving Bimzelx experienced a reduction in disease activity at Week 16, surpassing the 38% response rate observed in the Skyrizi cohort. This statistically significant outcome…

White House adds 600 generic meds to TrumpRx purchasing portal

June 16, 2026
The White House has announced the addition of 600 generic medications to its TrumpRx purchasing portal, a move aimed at enhancing the platform’s offerings amidst ongoing scrutiny regarding its effectiveness in lowering drug costs. This expansion comes as stakeholders in the pharmaceutical industry, particularly in regulatory and sourcing roles, seek clarity on the portal’s actual…

VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain

June 16, 2026
VERTANICAL has received breakthrough therapy designation from the US FDA for VER-01, its investigational non-opioid treatment for chronic low back pain. This designation is a significant milestone, as it underscores the potential of VER-01 to address a pressing medical need in a market often dominated by opioid prescriptions, which carry substantial risks of addiction and…

Regeneron Signs $2.32bn Deal with Parabilis for Helicon Conjugates

June 15, 2026
Regeneron Pharmaceuticals has entered into a significant $2.32 billion agreement with Parabilis Medicines aimed at the development of therapeutic candidates, particularly focusing on Antibody-Drug Conjugates (ADCs). This partnership underscores Regeneron’s commitment to expanding its oncology portfolio and leveraging innovative drug delivery systems to enhance therapeutic efficacy. The collaboration with Parabilis, known for its proprietary Helicon…

Ongoing Cases